We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Medigene AG (MDG1) NPV

Sell:€2.99 Buy:€3.04 Change: €0.06 (2.03%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: €0.06 (2.03%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: €0.06 (2.03%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Contact details

Lochhamer Strasse 11
+49 (89) 2000330

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€71.35 million
Shares in issue:
24.56 million
Frankfurt Stock Exchange

Key personnel

  • Gerd Zettlmeissl
    Chairman of the Supervisory Board
  • Dolores Schendel
    Chairman of the Executive Management Board, Chief Executive Officer, Chief Scientific Officer
  • Antoinette Hiebeler-Hasner
    Deputy Chairman of the Supervisory Board
  • Axelsven Malkomes
    Chief Financial Officer, Chief Business Development Officer, Member of the Management Board
  • Rene Goedkoop
    Acting Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.